Allergan shareholders will receive 0.8660 AbbVie shares and $120.30 in cash for each share held, for a total value of $188.24 per Allergan share.Biotech and Pharmaceuticalsread more
"What else do you have to do that will actually have to affect the Iranians' calculus?" said Amos Hochstein, who served as U.S. special envoy for international energy affairs...World Politicsread more
Reports of tensions may have been sparked by Kraft Heinz's underperformance and because of accounting problems at the packaged goods company.Investingread more
SpaceX used its high speed boat called "Ms. Tree" to catch the nosecone its Falcon 9 rocket after Monday's launch.Investing in Spaceread more
FedEx sued the U.S. government, saying it should not be held liable if it inadvertently shipped products that violated a Trump administration ban on exports to some Chinese...Traderead more
The major indexes have stretched to all-time highs and are riding one of their best first halves in decades.Trading Nationread more
The leaders of Japan and China got off to a tense start but have made significant progress in turning around their relations in recent years.Asia Politicsread more
Tech's hottest IPOs of the year, including Beyond Meat and Zoom, dropped on Monday, falling more than the broader market.Technologyread more
Citi Private Bank says it has maintained an "overweight" stance on stocks in China, Hong Kong, Taiwan and South Korea.Asia Marketsread more
Stocks in Asia slipped on Tuesday, while investors looked toward a meeting between U.S. President Donald Trump and Chinese President Xi Jinping set to happen later in the...Asia Marketsread more
A week of dovish fireworks out of the central banking community has just gone by with most of the world's leading central banks now guiding towards easing in light of downside...Commentaryread more
Pfizer's £69.4 billion ($110 billion) bid for U.K. pharmaceutical AstraZeneca was one of the biggest business stories of 2014 – so could a new bid be one of the biggest stories in 2015?
The only people with the answer are at Pfizer and its investment banks, and the tough rules and conditions of the U.K.'s Takeover Panel mean the U.S. group is unlikely to say anything until it is ready to announce it to the stock market.
Nonetheless, this hasn't stopped the guessing game in the stock markets.
On the one hand, the high-profile clampdown on tax inversion by the U.S. government means that Pfizer may not be as eager to pursue AstraZeneca as it once was. Another reason for Pfizer's interest in the U.K company -- entry into a much hoped-for new class of cancer drug – has been removed via an $850 million deal with Merck.
On the other, the U.S.'s tax action has yet to result in any definite legal decision. Pfizer still has a record of aggressive pursuit of acquisitions – and plenty of spare cash. Also, Actavis, one of the other companies Pfizer might have targeted, is off the block.
Neil Woodford, founding partner of Woodford Investment Management, one of the U.K.'s best-known fund managers and an AstraZeneca shareholder, rates the chances of a renewed AstraZeneca bid, although he argues that the U.K company would "achieve far better returns" without Pfizer.
Savvas Neophytou, pharmaceuticals analyst at Panmure Gordon, is closer to the general opinion of a 15-25 percent chance that there will be a renewed bid.
Pascal Soriot, AstraZeneca's chief executive, pledged revenues of $45 billion by 2023 in the light of the bid– but his more immediate pledge to get back to 2013 revenues by 2017 is going to be key to keeping shareholders onside in the medium term.
The company has promising new products in its immuno-oncology (a new kind of cancer treatment) and diabetes portfolio. It has also been boosted by Indian company Ranbaxy's failure to bring a cheaper generic replacement for heartburn treatment Nexium (which has $3.87 billion in annual global sales for AstraZeneca) to market as quickly as it had planned. Yet when generic Nexium inevitably arrives, the revenue slide could be unflattering to management.
If nothing else, AstraZeneca's time in the spotlight earlier in the year has helped refocus the attention of those who had dismissed it. Yet the share price still has far to climb from its current £46.69 levels to the £55 a share Pfizer put on the table – and the company's management are now under increased pressure to deliver.
- By CNBC's Catherine Boyle